Form 4: Tyra Biosciences COO Daniel Bensen Sells Shares Under 10b5-1 Trading Plan

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, sold shares of common stock over three days in late February under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Bensen, the Chief Operating Officer of Tyra Biosciences, sold shares of the company's common stock on February 27, 28, and 29, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 7, 2022.
• On February 27, 745 shares were sold at a price of $20.
• On February 28, 5,849 shares were sold at a weighted average price of $20.128, with individual prices ranging from $20.00 to $20.50.
• On February 29, 2,050 shares were sold at a weighted average price of $20.0016, with individual prices ranging from $20.00 to $20.02.
• Following these transactions, Bensen directly owns 442,836 shares of Tyra Biosciences common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock sales by an insider under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. The use of a 10b5-1 trading plan suggests that these sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates concerns about insider information.

Key Dates